Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2448-2454

  O'Mara, Edward ^a   Kasserra, Claudia ^a   Huddlestone, John Robert ^b   Wan, Yuntao ^a,f   Soni, Peter ^a   Caceres, Maria ^a   Medlock, Matthew ^c   Morrison, Royce ^d   Devinsky, Orrin ^e  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Neurology and Neurosurgery Associates   (United States)

^c Pharmaceutical Product Development   (United States)

^d CHARLES RIVER LABORATORIES   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; PLACEBO; RITONAVIR; VICRIVIROC;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARRHYTHMOGENESIS; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG WITHDRAWAL; EEG ABNORMALITY; ELECTROCARDIOGRAM; ELECTROENCEPHALOGRAM; EPILEPTOGENESIS; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; NEUROPHARMACOLOGY; NORMAL HUMAN; PATIENT COMPLIANCE; POLLAKISURIA; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ARRHYTHMIAS, CARDIAC; CENTRAL NERVOUS SYSTEM; ELECTROCARDIOGRAPHY; ELECTROENCEPHALOGRAPHY; FEMALE; HEART; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; RECEPTORS, CCR5; RITONAVIR; YOUNG ADULT;

EID: 77952635258     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01447-09     Document Type: Article

References (11)

1. Algra, A., J. G. Tijssen, J. R. Roelandt, J. Pool, and J. Lubsen. 1991. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 83:1888-1894.
2. Buckingham, T. A., Z. R. Bhutto, E. A. Telfer, and J. Zbilut. 1994. Differences in corrected QT intervals at minimal and maximal heart rate may identify patients at risk for torsades de pointes during treatment with antiarrhythmic drugs. J. Cardiovasc. Electrophysiol. 5:408-411.
3. Démolis, J. L., D. Kubitza, L. Tenneze, and C. Funck-Brentano. 2000. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin. Pharmacol. Ther. 68:658-666.
4. Gulick, R., D. Haas, A. C. Collier, J. Lennox, C. Parker, and W. Greaves. 2007. Two-year follow-up of treatment-experienced patients on vicriviroc (VCV). Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., abstr. H-1030.
5. Gulick, R. M., Z. Su, C. Flexner, M. D. Hughes, P. R. Skolnik, T. J. Wilkin, R. Gross, A. Krambrink, E. Coakley, W. L. Greaves, A. Zolopa, R. Reichman, C. Godfrey, M. Hirsch, and D. R. Kuritzkes. 2007. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. J. Infect. Dis. 196:304-312.
6. Jasper, H. H. 1958. The ten-twenty electrode system of the International Federation. Electroencephalogr. Clin. Neurophysiol. 10:371-375.
7. Noel, G. J., J. Natarajan, S. Chien, T. L. Hunt, D. B. Goodman, and R. Abels. 2003. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin. Pharmacol. Ther. 73:292-303.
8. K-blocking drugs. Circulation 103:2207-2212.
9. U.S. Food and Drug Administration. 2005. Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. U.S. Food and Drug Administration, Rockville, MD.
10. Wu, Y., and M. E. Anderson. 2002. Reduced repolarization reserve in ventricular myocytes from female mice. Cardiovasc. Res. 53:763-769.
11. Zingman, B., J. Suleiman, E. DeJesus, J. Slim, C. Mak, M. McCarthy, N. Case, and L. Dunkle. 2008. Vicriviroc in combination therapy with an optimized ART regimen for treatment-experienced subjects: VICTOR-E1, poster 795. 15th Conf. Retrovir. Opportunistic Infect., Boston, MA.